This report takes an in-depth look at the veterinary vaccines
industry detailing:
Veterinary Vaccines: Products and markets provides you with product analysis for classical vaccines, new vaccine types and other research avenues. The company profiles cover company vaccine interests, major geographical markets, major species targets, notable additions to the range and vaccine research activity.
Companies profiled: * Bayer * Boehringer Ingelheim * Fort Dodge * Hoechst Roussel Vet * Intervet * Merial * Pfizer * Schering-Plough.
National market profiles cover: * Argentina * Brazil * France * Germany * Japan * Mexico * Netherlands * Spain * UK * US.
PUBLISHED: AUGUST 1999
REF: SR188E
PAGES: 128
PRICE: £450/$945/¥108,000
For further information about this report, please contact our Customer Helpdesk on:
Tel: +44 (0)20 8332 8965 / 66
Fax: +44 (0)20 8332 8992
E-mail: [email protected]
CONTENTS
LIST OF TABLES
EXECUTIVE SUMMARY
ABBREVIATIONS
CHAPTER 1 VACCINE TECHNOLOGY AND RESEARCH
ACTIVITY
1.1 Classical immunology
1.1.1 Live vaccines
1.1.2 Inactivated vaccines
1.1.3 Toxoids
1.1.4 Limitations of classical technologies
1.2 New vaccine types
1.2.1 Gene-deleted vaccines
1.2.2 Sub-unit vaccines
1.2.3 Vectored vaccines
1.3 Other research avenues
1.3.1 DNA vaccines
1.3.2 Synthetic vaccines
1.3.3 Edible vaccines
1.3.4 Disabled infectious single cycle-virus technology
1.3.5 Adjuvant technology
1.3.6 Vaccine delivery
1.4 Key vaccine targets and current research projects
CHAPTER 2 MAJOR VACCINE TARGETS
2.1 Foot and mouth disease
2.1.1 Europe
2.1.2 South America
2.1.3 Rest of the world
2.2 Rabies
2.3 Cattle disease targets
2.3.1 Bovine respiratory disease complex
2.3.2 Clostridial infections
2.3.3 Bovine mastitis
2.3.4 Parasitic infections
2.4 Sheep disease targets
2.4.1 Clostridial infections
2.4.2 Pasteurella infections
2.5 Pig disease targets
2.5.1 Transmissible gastro-enteritis
2.5.2 Aujeszky's disease
2.5.3 Atrophic rhinitis
2.5.4 Porcine reproductive and respiratory syndrome
2.5.5 Classical swine fever
2.5.6 Mycoplasmal pneumonia
2.5.7 Swine erysipelas
2.5.8 Enteric colibacillosis
2.5.9 Salmonella
2.6 Poultry disease targets
2.6.1 Newcastle disease
2.6.2 Marek's disease
2.6.3 Infectious bursal disease
2.6.4 Infectious bronchitis
2.6.5 Avian influenza
2.6.6 Coccidiosis
2.6.7 Salmonella
2.7 Small animal disease targets
2.7.1 Multivalent canine disease targets
2.7.2 Multivalent feline disease targets
2.7.3 Canine Lyme disease
2.7.4 Feline leukaemia virus
2.7.5 Feline immunodeficiency virus
2.7.6 Feline infectious peritonitis
2.7.7 Antiparasitic and allergy vaccines
2.8 Equine disease targets
2.8.1 Equine viral rhinopneumonitis
2.8.2 Equine influenza
2.8.3 Tetanus
CHAPTER 3 THE MARKET FOR VETERINARY VACCINES
3.1 The world market for veterinary vaccines
3.1.1 Market value and recent growth
3.1.2 Factors affecting recent biologicals sales growth
3.1.3 World biologicals sales by region
3.1.4 World biologicals sales by species
3.2 Major national market profiles
3.2.1 The US
3.2.2 Brazil
3.2.3 Japan
3.2.4 Germany
3.2.5 France
3.2.6 UK
3.2.7 Spain
3.2.8 Mexico
3.2.9 The Netherlands
3.2.10 Argentina
3.3 Future prospects for the world biologicals market
3.3.1 The supply of new and improved products
3.3.2 Animal populations
3.3.3 Patterns of disease incidence
3.3.4 Trade and regulatory issues
3.3.5 Global and regional economic performance
3.3.6 Political and social attitudes
CHAPTER 4 LEADING COMPANIES IN THE VETERINARY
VACCINES MARKET
4.1 Vaccine market characteristics
4.2 Vaccine market shares
4.2.1 Changes in ownership of major vaccine market shares
4.2.2 Market leaders and shares
4.3 Leading company profiles
4.3.1 Fort Dodge
4.3.2 Merial
4.3.3 Pfizer
4.3.4 Intervet
4.3.5 Schering-Plough
4.3.6 Bayer
4.3.7 Hoechst Roussel Vet
4.3.8 Boehringer Ingelheim
REFERENCES AND EXHANGE RATES
LIST OF TABLES
Table 1.1 Limitations of classical vaccines
Table 1.2 Gene-deleted Aujeszky's disease vaccines
Table 1.3 Marker vaccine development projects
Table 1.4 Commercially available vectored vaccines
Table 1.5 Vectored vaccine development projects
Table 1.6 Current vaccine research projects
Table 2.1 Number of animals vaccinated against foot and mouth
disease, 1997
Table 2.2 Classical swine fever outbreaks in the EU, 1997
Table 3.1 Recent growth of the world market for biologicals,
1993-1998
Table 3.2 Exchange rate impacts on biological market values,
1996-1997
Table 3.3 Per capita beef/veal consumption in selected European
markets, 1995-1998
Table 3.4 Poultry meat consumption by region, 1994 and 1998
Table 3.5 World biologicals sales by region, 1998
Table 3.6 World biologicals sales by species, 1998
Table 3.7 Leading national markets for biologicals, 1998
Table 3.8 Vaccine sales growth in selected major markets, 1993
and 1998
Table 3.9 US biologicals sales and total market growth, 1993-1998
Table 3.10 US biologicals sales by species, 1998
Table 3.11 Brazilian biologicals sales and total market growth,
1993 and 1998
Table 3.12 Japanese biologicals sales and total market growth,
1992-1997
Table 3.13 Japanese biologicals sales by species, 1994 and 1997
Table 3.14 German biologicals sales and total market growth,
1992-1998
Table 3.15 German biologicals sales by species, 1998
Table 3.16 French biologicals sales and total market growth,
1992-1997
Table 3.17 French biologicals sales by species, 1994 and 1997
Table 3.18 UK biologicals sales and total market growth,
1992-1998
Table 3.19 UK biologicals sales by species, 1995 and 1998
Table 3.20 Spanish market structure and growth, 1997-1998
Table 3.21 Mexican biologicals sales and total market structure,
1998
Table 3.22 Mexican biologicals sales by species, 1998
Table 3.23 Dutch biologicals sales and total market growth,
1993-1997
Table 3.24 Argentinean biologicals sales and total market growth,
1993-1998
Table 3.25 Argentinean biologicals sales by species, 1998
Table 3.26 Cattle numbers in major vaccine markets, 1994 and 1999
Table 4.1 Relative concentration of the animal health and vaccine
markets, 1998
Table 4.2 Veterinary biological interests of the 20 animal health
and nutrition market leaders
Table 4.3 Recent corporate activity in the veterinary vaccines
sector, 1995-1998
Table 4.4 Leading companies and vaccine market shares, 1998
Table 4.5 Relative importance of biologicals sales to revenues of
the market leaders, 1998
Table 4.6 Fort Dodge Animal Health sales, 1994-1998
Table 4.7 Merial Animal Health sales, 1997-1998
Table 4.8 Merial animal health sales by major product category,
1998
Table 4.9 Pfizer Animal Health sales, 1994-1998
Table 4.10 Key elements of the Pfizer vaccines range
Table 4.11 Intervet animal health sales, 1994-1998
Table 4.12 Schering-Plough Animal Health sales, 1994-1998
Table 4.13 Schering-Plough Animal Health biologicals sales by
species, 1998
Table 4.14 Bayer animal health sales, 1994-1998
Table 4.15 Bayer's vaccine sales by species, 1998
Table 4.16 Bayer's vaccine sales by market region, 1998
Table 4.17 Hoechst Roussel Vet sales, 1994-1998
Table 4.18 Hoechst Roussel Vet sales by major product category,
1998
Table 4.19 Boehringer Ingelheim Vetmedica sales, 1994-1998
Table 4.20 Boehringer Ingelheim Vetmedica biologicals sales by
region, 1998
Table 4.21 Boehringer Ingelheim Vetmedica biologicals sales by
species, 1998
EXECUTIVE SUMMARY
Veterinary vaccines generated global sales of more than $2.4
billion in 1998, accounting for approximately 14% of the world
market for animal health and nutrition products. Excluding the
nutritional feed additives market, the vaccine share of core
veterinary product sales rose to more than 17% in 1998. This rise
can be attributed to an increase of new products in the vaccine
sector. Broader applications of immunological disease control
combined with low growth in other product sectors will see
vaccines command an increasingly larger share of the world market
for animal health products in the 21st century.
Classical live and inactivated vaccines dominated the veterinary biologicals market until the early 1980s, when modern biotechnological advances began to offer new approaches to vaccine construction, design, and manufacture. The new technologies enabled improvements to be made in both the safety and efficacy of vaccine products. They also encouraged research into vaccines against new viral, bacterial, and parasite targets and the expansion of immunological applications into new areas.
The success of those research efforts has seen a growth in the type and number of high-tech vaccines brought to market since the early 1980s. Three major new vaccine types - gene deleted products, vectored vaccines, and sub-unit vaccines - have been successfully commercialised, and have already had a significant impact both on the ability to control or eradicate animal disease, and on the structure of the biologicals market.
The new technology of deleting one or more of the appropriate genes from target pathogens renders them non-pathogenic, increasing the safety of gene-deleted or marker vaccines. Deletions also enable serological distinctions between vaccinated animals and those exposed to natural or 'field' organisms. The usage of gene-deleted vaccines and associated testing techniques has played a major part in the efforts to eradicate infections such as Aujeszky's disease and infectious bovine rhinotracheitis.
Sub-unit vaccines are constructed using the fractions of a target pathogen that are responsible for inducing immunological responses. Target material is manufactured using expression systems before extraction and purification but prior to use in sub-unit vaccines. The resulting sub-unit products have been commercialised for use in a range of species, including pigs, cattle, sheep, horses, and small animals.
The insertion of protective antigens into modified viral or bacterial 'vector' material enables accurate and refined delivery of the vaccine to the required sites of action. The use of vectors has enabled manufacturers to overcome the sometimes limited immunogenicity of sub-unit products. The Vaccinia virus was widely used in early products, but now an increasing range of viral and bacterial hosts are being utilised in both commercial vectored vaccines and development-stage products.
In the past 10 to 15 years, the boundaries of vaccine coverage have been expanding - notably in the companion animal sector where products against feline leukaemia, canine Lyme disease, and feline infectious peritonitis have all been commercialised. Key new targets for immunological control are being addressed in a variety of species, and vaccines will eventually be used against an increasing range of viral, bacterial, and parasitic problems. Improved protection is eventually expected against diseases such as bovine mastitis and poultry coccidiosis. Vaccines against major parasites in both livestock and companion animals are also in development, while immunological products for the control of reproduction will eventually be made available for use in a range of species.
The first two chapters of this report look in detail at the technologies being used to improve the safety and efficacy of veterinary vaccines, and at the range of vaccine targets now under scrutiny by commercial and academic organisations. Chapters Three and Four examine commercial aspects, profiling the market for veterinary vaccines and the leading companies active in the sector.
The existing results of high-tech approaches to vaccine design and the potential of such approaches have attracted a broad range of research specialists into the sector. National markets for the manufacture and marketing of vaccines are well populated, but commercial activity at a global level is the domain of only a few multinational companies. The market leader, Fort Dodge, generates roughly 15% of total global vaccine sales, while the remaining top five companies account for a total share of nearly 60%. This report profiles the businesses of eight leading players, between them responsible for more than 70% of world vaccine sales.
The report also looks in detail at the size and structure of the vaccines market, which is led by sales in the EU and North America. These two regions together account for more than half of the total world market. Other key regional markets include South America and the Far East. The markets of 10 countries are profiled in depth, and they are responsible for close to two-thirds of global vaccine sales. Individual profiles examine recent rates of market growth, the structure of individual markets by species, and prospects for future sales growth.
© PJB Publications Ltd. 2000 All rights reserved. |